Adherence-enhancing intervention and relapse in childhood acute lymphoblastic leukemia: results from the Children’s Oncology Group randomized trial ACCL1033
Year: 2026
Type: article
Study design: Clinical Trial
Abstract: Durable remissions in children with acute lymphoblastic leukemia (ALL) require an 18-to-24-month-long maintenance phase with daily self-administered oral mercaptopurine (6MP) [ 1 , 2 , 3 , 4 ]. In a previous multicenter study, we showed that 6MP adherence rates <95% were associated with a 2.7-fold higher relapse risk [ 4 ]. Over 40% of relapses in children entering maintenance in first remission were attributable to suboptimal 6MP adherence [ 4 , 5 , 6 ]. The most common reason for missing 6MP was forgetfulness [ 5 ]; adherent patients endorsed parental vigilance to overcome forgetfulness [ 7 ].
Source: Leukemia
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
Awards: G1318605484, G1504112592, G2901481919, G3647844574, Children's Oncology Group Statistics and Data Center, Comprehensive Approach to Improve Medicine Adherence in Pediatric Leukmia, G6520272241, G6778764405, Children's Oncology Group NCI Community Oncology Research Program (NCORP) Research Base grant, G778972947, G9000026463, G9000035374, G9000077681, G9000122489, G997771125
OpenAlex ID: W7154073254
